Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

Help May be On the Way for Patients with Parkinson's Disease

Press Releases April 20, 2021

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson's Disease

GlobeNewswire April 20, 2021

PharmaTher Provides Update on Psychedelic Product Programs

Canadian Press, with file by Stockhouse April 15, 2021

Newscope Announces Name Change to PharmaTher Holdings Ltd.

GlobeNewswire April 13, 2021

Newscope Announces Name Change

GlobeNewswire April 8, 2021

Newscope Capital Provides Dial-In Information for Special Meeting

GlobeNewswire April 1, 2021

PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

PR Newswire March 24, 2021

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

GlobeNewswire March 19, 2021

World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

GlobeNewswire March 16, 2021

Ketamine Could Potentially Increase Life Expectancy for Lou Gehrig's Disease Patients

Livemoney March 2, 2021

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease

GlobeNewswire March 2, 2021

Newscope Announces DTC Eligibility of Its Common Shares in the United States

GlobeNewswire March 1, 2021

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

GlobeNewswire February 23, 2021

PharmaTher Announces Sale of Psilocybin Program

GlobeNewswire February 17, 2021

PharmaTher Announces Successful Completion of Pre-IND Meeting with FDA for the Clinical Development of Ketamine in the Treatment of Parkinson's Disease

GlobeNewswire February 4, 2021

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine

GlobeNewswire February 1, 2021

Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

GlobeNewswire January 22, 2021

PharmaTher (CSE:PHRM) signs license agreement for patented Ketamine formulation targeting mental health

Isabella Zavarise January 19, 2021

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

GlobeNewswire January 19, 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

GlobeNewswire January 14, 2021